

## Targeting KRAS in advanced NSCLC

### Chair

Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, USA

### Faculty

Benjamin Besse, MD, Gustave Roussy Cancer Campus, Villejuif, France

Ramaswamy Govindan, MD, Washington University School of Medicine, St. Louis, MO, USA

**Release date: September 10, 2021**

**Expiration date: September 10, 2022**

**Estimated time to completion: 1.0 hour**

**Available CME Credits: up to 1.0 AMA PRA Category 1 Credit(s)<sup>™</sup>**

### Activity description

This educational activity consists of one Expert Discussion and one Interactive Infographic.

During the Expert Discussion, leading experts will provide you with insights on acknowledging clinically relevant features of Kirsten rat sarcoma viral oncogene (KRAS) mutations in non-small-cell lung cancer (NSCLC), such as their prognostic and predictive value as a biomarker, and on implementing advanced diagnostic strategies in order to identify specific populations with targetable mutations; they will also discuss clinical updates on the emerging targeted treatment options for KRAS-driven NSCLC.

The Interactive Infographic will provide an overview of the oncogenic driver landscape in NSCLC and briefly touch on the epidemiology, cell signaling, and oncogenic mechanisms of KRAS.

### Target audience

This activity is intended for oncologists, pathologists, pulmonologists, and other healthcare professionals involved in the diagnosis, treatment, and management of patients with NSCLC.

### Educational objectives

After completing this activity, the participant should be better able to:

- **Identify** clinically relevant features of KRAS mutations in NSCLC and evaluate their prognostic and predictive value as a biomarker
- **Implement** advanced diagnostic strategies in order to identify specific populations with targetable mutations such as KRAS mutations
- **Discuss** emerging targeted treatment options for KRAS-driven NSCLC

### Joint accreditation statement

In support of improving patient care, this activity has been planned and

implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

### Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of up to 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period September 10, 2021, through September 10, 2022:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. View the webcast and the interactive infographic
3. Take the post-activity test and complete the evaluation
4. Indicate the number of credits earned and download the certificate of CME credit

### Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Alexander Drilon, MD	Consultant for: AbbVie, AstraZeneca, ArcherDX, BeiGene, BergenBio, Blueprint Medicines, Chugai Pharmaceutical Co., Elevation Oncology (formerly 14ner Oncology), EMD Serono, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche,

	<p>Loxo/Bayer/Lilly, Liberum, Melendi, Monopteros Therapeutics, MORE Health, Novartis, Pfizer, Remedica Ltd, Repare Therapeutics, Takeda/Ariad/Millennium, Turning Point Therapeutics, Tyra Biosciences, Verastem Oncology</p> <p>Contracted researcher for: Exelixis, GSK, Pfizer, PharmaMar, Teva, Taiho</p> <p>Non-CE services (e.g. Speakers bureaus): Axis, Medscape, MJH Life Sciences™, OncLive, Paradigm Medical Communications, Peerview Institute, PeerVoice, Physicians' Education Resource®, Research Yo Practice, Targeted Oncology, WebMD.</p> <p>Royalties: Wolters Kluwer</p>
Benjamin Besse, MD	<p>Contracted researcher for: AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, Ipsen, Inivata, Janssen, Merck KGaA, MSD, Nektar Therapeutics, Onxeo, OSE Immunotherapeutics, Pfizer, PharmaMar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, Tolero Pharmaceuticals</p>
Ramaswamy Govindan, MD	<p>Consultant for: Inivata, GenePlus, Merck, Precisca</p>

### Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

### Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



### Financial support

This activity is supported by educational funding provided by Amgen.

**Disclosure of unlabeled use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

**Contact information for questions about the activity**

[info@ologyeducation.org](mailto:info@ologyeducation.org), [www.ologyeducation.org](http://www.ologyeducation.org)  
[inquiries@pimed.com](mailto:inquiries@pimed.com), [www.pimed.com](http://www.pimed.com)

**System requirements**

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

**Policy on Privacy and Confidentiality**

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

**Media**

Internet